Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06038578 · ClinicalTrials.gov registry record · Phase 2

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

A Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, sponsored by Toray Industries.

Recruiting
Registry status
Phase 2
Development phase
146
Enrollment target
20
Study locations

NCT06038578 is a Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma that is actively recruiting participants, run by Toray Industries. The registered enrollment target is 146 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06038578, a Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, is actively recruiting participants, sponsored by Toray Industries.

RECRUITING
Registry status
Phase 2
Development phase
146 participants
Enrollment target
20
Study locations

Study Summary

This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.

Conditions Studied

Gastric Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Interventions

  • DRUG Paclitaxel
  • DRUG Ramucirumab
  • BIOLOGICAL TRK-950

Study Locations (20)

Texas

  • Texas Oncology Arlington North - Arlington
  • Texas Oncology Bedford - Bedford
  • Texas Oncology Dallas Methodist - Dallas
  • Texas Oncology Dallas Medical City - Dallas
  • Texas Oncology Dallas Presbyterian - Dallas
  • Texas Oncology Methodist Charlton Cancer Center - Dallas
  • Texas Oncology-Sammons Cancer Center - Dallas
  • Texas Oncology Fort Worth Cancer Center - Fort Worth
  • Texas Oncology Grapevine - Grapevine
  • Texas Oncology Plano East - Plano
  • Texas Oncology Plano West - Plano

California

  • City of Hope - Duarte
  • City of Hope at Orange County Lennar Foundation Cancer Center - Irvine
  • University of California, Los Angeles - Santa Monica

Other

  • National Cancer Center Hospital - Chūōku
  • Osaka International Cancer Institute - Chūōku
  • National Cancer Center Hospital East - Kashiwa

Kanagawa

  • Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center - Yokohama

Saitama

  • Saitama Prefectural Hospital Organization Saitama Cancer Center - Shinden

Shizuoka

  • Shizuoka Cancer Center - Nagaizumi-cho

Trial Details

FieldValue
Enrollment Target 146 participants
Start Date 2023-10-04
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

Toray Industries

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06038578

The ClinicalTrials.gov registry entry for NCT06038578 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (54% lower). The listed sponsor is Toray Industries, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Paclitaxel is the first listed.

NCT06038578 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Texas, California, Other.

Frequently Asked Questions

What is clinical trial NCT06038578 about?

NCT06038578 is a clinical study titled "A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer". This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarc...

What is the current status of trial NCT06038578?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2023-10-04. Estimated completion is 2026-06-30.

What conditions does trial NCT06038578 study?

This clinical trial studies the following conditions: Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.

What interventions are being tested in trial NCT06038578?

The interventions under investigation include: Paclitaxel (DRUG), Ramucirumab (DRUG), TRK-950 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06038578?

This trial is sponsored by Toray Industries, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06038578 being conducted?

This trial has 20 study locations across California, Texas, Kanagawa, Saitama, Shizuoka. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Gastric Adenocarcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.